Seraseq® ctDNA Mutation Mix v2 AF1%

To overcome the lack of patient-like reference materials for liquid biopsy, including drawbacks of existing methodologies such as sonication, SeraCare has developed a breakthrough technology that produces the most patient-like materials compared to native ctDNA. The Seraseq ctDNA Mutation Mix v2 is a highly multiplexed product for NGS-based ctDNA assays targeting cancer-relevant somatic mutations.

This specific ctDNA Mutation Mix v2 product has an allele frequency of 1%.

• Size distribution, library yield and complexity consistent with native ctDNA
• Single sample with 40 clinically-relevant mutations across 28 genes, all at the same specified allele frequency
• Offered as a purified DNA mixture for ease of use during assay development
• Mutation targets precisely quantitated with digital PCR
• Single well-characterized GM24385 human genomic DNA as background wild-type material
• Manufactured in GMP-compliant and ISO 13485-certified facilities

Find more data and in-depth technical information by reading this technical product report.

Liquid Biopsy FAQs

Review the common questions we receive from our customers and the responses we provide.

LEARN MORE